SYNCROVAX Trademark

Trademark Overview

On Tuesday, January 25, 2022, a trademark application was filed for SYNCROVAX with the United States Patent and Trademark Office. The USPTO has given the SYNCROVAX trademark a serial number of 97238141. The federal status of this trademark filing is THIRD EXTENSION - GRANTED as of Thursday, June 27, 2024. This trademark is owned by Syncromune, Inc.. The SYNCROVAX trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical products for the treatment of cancer
syncrovax

General Information

Serial Number97238141
Word MarkSYNCROVAX
Filing DateTuesday, January 25, 2022
Status732 - THIRD EXTENSION - GRANTED
Status DateThursday, June 27, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 6, 2022

Trademark Statements

Goods and ServicesPharmaceutical products for the treatment of cancer

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, January 31, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameSyncromune, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressFort Lauderdale, FL 33308
Party NameSyncromune, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressFort Lauderdale, FL 33339

Trademark Events

Event DateEvent Description
Friday, January 28, 2022NEW APPLICATION ENTERED
Monday, January 31, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, November 3, 2022ASSIGNED TO EXAMINER
Thursday, November 3, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, November 16, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, December 6, 2022PUBLISHED FOR OPPOSITION
Tuesday, December 6, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, January 31, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, July 19, 2023DIVISIONAL REQUEST RECEIVED
Wednesday, July 19, 2023TEAS REQUEST TO DIVIDE RECEIVED
Tuesday, July 25, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, July 25, 2023SOU EXTENSION 1 FILED
Thursday, August 3, 2023CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, August 3, 2023SOU EXTENSION 1 GRANTED
Friday, August 4, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, January 25, 2024SOU TEAS EXTENSION RECEIVED
Thursday, January 25, 2024SOU EXTENSION 2 FILED
Thursday, January 25, 2024SOU EXTENSION 2 GRANTED
Saturday, January 27, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, February 1, 2024DIVISIONAL PROCESSING COMPLETE
Friday, February 2, 2024CORRECTED NOA E-MAILED
Thursday, June 27, 2024SOU TEAS EXTENSION RECEIVED
Thursday, June 27, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, June 27, 2024SOU EXTENSION 3 FILED
Thursday, June 27, 2024SOU EXTENSION 3 GRANTED

Related Keywords

syncrovax cancer treatment products pharmaceutical